Prognostic Value of Cardiac 123I-Metaiodobenzylguanidine Imaging in Patients With Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction

Prognostic Value of Cardiac 123I-Metaiodobenzylguanidine Imaging in Patients With Stabilized Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction - Prognostic Value of 123I-MIBG in CHF

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000000626

Enrollment

200

Registered

2007-03-03

Start date

1999-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Definitive signs and symptoms of decompensated acute heart failure and required hospitalization 2)Left ventricular ejection fraction (LVEF) of less than 45% 3)No cardiac events for at least 5 months after hospital discharge 4)Fully informed consent was obtained

Exclusion criteria

Exclusion criteria: 1)Congenital heart disease 2)Unstable angina 3)Acute myocardial infarction 4)Hepatic failure 5)Renal failure 6)Active cancer 7)Severe heart failure requiring mechanical support (intraaortic balloon pumping, left ventricular assist device, or cardiac resynchronization therapy) 8)Requiring heart transplantation

Design outcomes

Primary

Measure	Time frame
Fatal cardiac events during the study.	—

Countries

Japan

Contacts

Public ContactShu Kasama

Kitakanto Cardiovascular Hospital Internal Medicine

s-kasama@bay.wind.ne.jp027-232-7111

Outcome results